Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer
Drug guidance

Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer

Condition

Cancer

Endocrine and metabolic

4 January 2022

Published on 04 Jan 2022
Last Updated on 04 Jan 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

  • Dabrafenib 50 mg and 75 mg capsules in combination with trametinib 0.5 mg and 2 mg tablets for treating locally advanced or metastatic anaplastic thyroid cancer in patients with a BRAF V600 mutation and with no satisfactory locoregional treatment options.

Subsidy status

Dabrafenib 50 mg and 75 mg capsules and trametinib 0.5 mg and 2 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 4 January 2022.

Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.

Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer (4 Jan 2022) [PDF, 123 KB]

PES Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer (Published 4 Jan 2022) [PDF, 90 KB]

Back to top